Aviva PLC Acquires 38,765 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Aviva PLC raised its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 39.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 137,413 shares of the biopharmaceutical company’s stock after acquiring an additional 38,765 shares during the quarter. Aviva PLC owned approximately 0.11% of Halozyme Therapeutics worth $6,570,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in HALO. Smartleaf Asset Management LLC lifted its stake in Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 197 shares during the last quarter. Louisiana State Employees Retirement System increased its holdings in shares of Halozyme Therapeutics by 0.6% during the fourth quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company’s stock worth $1,688,000 after buying an additional 200 shares in the last quarter. State of New Jersey Common Pension Fund D boosted its holdings in shares of Halozyme Therapeutics by 0.6% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company’s stock valued at $2,279,000 after acquiring an additional 302 shares in the last quarter. Parkside Financial Bank & Trust grew its position in Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 322 shares during the last quarter. Finally, Nations Financial Group Inc. IA ADV increased its holdings in Halozyme Therapeutics by 2.4% in the 4th quarter. Nations Financial Group Inc. IA ADV now owns 14,062 shares of the biopharmaceutical company’s stock worth $672,000 after purchasing an additional 328 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 5,000 shares of the company’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the transaction, the director now owns 38,611 shares in the company, valued at approximately $2,173,799.30. This represents a 11.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total value of $580,500.00. Following the completion of the sale, the senior vice president now directly owns 185,453 shares of the company’s stock, valued at $10,765,546.65. The trade was a 5.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 22,200 shares of company stock valued at $1,286,568. 2.40% of the stock is currently owned by company insiders.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $57.54 on Wednesday. The company has a market capitalization of $7.11 billion, a PE ratio of 16.78, a P/E/G ratio of 0.42 and a beta of 1.32. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics, Inc. has a twelve month low of $37.73 and a twelve month high of $66.00. The firm has a fifty day simple moving average of $59.96 and a 200 day simple moving average of $54.83.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The firm had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. On average, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Benchmark reissued a “buy” rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Piper Sandler lifted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. Wells Fargo & Company decreased their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Finally, HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $62.78.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.